Bharat Biotech Signs Pact With CSIR-IICT For Development Of Novel Vaccine, Bio-Therapeutics Platforms

Bharat Biotech, Biovet and Sapigen Biologix have signed a Master Collaborative Agreement (MCA) with the Council Of Scientific And Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT) to develop novel platform technologies for vaccines and bio-therapeutics.

The development of these novel technologies will support the affordable healthcare solutions for humans and animals.

The agreement was signed in the presence of Bharat Biotech CMD Dr Krishna Ella, CSIR DG Shekhar C Mande and IICT Director S Chandrasekhar.

As per the agreement, the CSIR-IICT will receive financial aid from the industry collaborators for developing key raw materials required by the firms.

The CSIR-IICT will also conduct “in-vitro and in vivo studies” for the potential vaccine candidates and also the bio-therapeutics formulations that will be designed by the collaborators, reports Economic Times.

The partners of this initiative aim to carry out studies on futuristic vaccines, delivery strategies and also bio-therapeutic formulations.

The partners will also explore certain innovative solutions to the vaccine administration processes. Moreover, this MCA allows the participants to undertake futuristic development activities in other related areas too.